Home Glenmark's Novel Monoclonal Antibody GBR 900 For Treatment Of Chronic Pain Entering Human Trials
 

Keywords :   


Glenmark's Novel Monoclonal Antibody GBR 900 For Treatment Of Chronic Pain Entering Human Trials

2014-04-30 07:12:40| drugdiscoveryonline News Articles

Glenmark Pharmaceuticals S.A., a wholly owned Swiss subsidiary of Glenmark Pharmaceuticals Ltd., announced today that GBR 900, a novel monoclonal antibody is entering human trials

Tags: human treatment pain entering

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
17.05House Republicans release farm bill draft
17.05House Republicans release farm bill draft
17.05Union forming stalled in US Mercedes-Benz
17.05Johnson & Johnson Acquires Atopic Dermatitis Treatment Biotech Company
More »